Scinopharm Taiwan Stock Debt To Equity

1789 Stock  TWD 22.20  0.50  2.20%   
ScinoPharm Taiwan fundamentals help investors to digest information that contributes to ScinoPharm Taiwan's financial success or failures. It also enables traders to predict the movement of ScinoPharm Stock. The fundamental analysis module provides a way to measure ScinoPharm Taiwan's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ScinoPharm Taiwan stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ScinoPharm Taiwan Company Debt To Equity Analysis

ScinoPharm Taiwan's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

 = 

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current ScinoPharm Taiwan Debt To Equity

    
  21.10 %  
Most of ScinoPharm Taiwan's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ScinoPharm Taiwan is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

According to the company disclosure, ScinoPharm Taiwan has a Debt To Equity of 21.1%. This is 60.59% lower than that of the Pharmaceuticals sector and 74.88% lower than that of the Health Care industry. The debt to equity for all Taiwan stocks is 56.67% higher than that of the company.

ScinoPharm Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ScinoPharm Taiwan's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ScinoPharm Taiwan could also be used in its relative valuation, which is a method of valuing ScinoPharm Taiwan by comparing valuation metrics of similar companies.
ScinoPharm Taiwan is currently under evaluation in debt to equity category among its peers.

ScinoPharm Fundamentals

About ScinoPharm Taiwan Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ScinoPharm Taiwan's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ScinoPharm Taiwan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ScinoPharm Taiwan based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for ScinoPharm Stock Analysis

When running ScinoPharm Taiwan's price analysis, check to measure ScinoPharm Taiwan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ScinoPharm Taiwan is operating at the current time. Most of ScinoPharm Taiwan's value examination focuses on studying past and present price action to predict the probability of ScinoPharm Taiwan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ScinoPharm Taiwan's price. Additionally, you may evaluate how the addition of ScinoPharm Taiwan to your portfolios can decrease your overall portfolio volatility.